A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma.
D. D. Eisenstat
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
L. B. Nabors
Consultant or Advisory Role - Boehringer Ingelheim (U)
W. P. Mason
No relevant relationships to disclose
J. R. Perry
No relevant relationships to disclose
W. R. Shapiro
Research Funding - Boehringer Ingelheim
P. Kavan
No relevant relationships to disclose
S. Phuphanich
Research Funding - Boehringer Ingelheim
Y. Fu
Employment or Leadership Position - Boehringer Ingelheim
X. J. Cong
Employment or Leadership Position - Boehringer Ingelheim
M. Shahidi
Employment or Leadership Position - Boehringer Ingelheim (U)
D. A. Reardon
Consultant or Advisory Role - EMD Serono
Honoraria - EMD Serono; Genentech; Merck; Roche; Schering-Plough